8 completed, 1 terminated. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Terminated 1 |
Follow Chemotherapy-induced Nausea and Vomiting: new trials by email Literature Review of Chemotherapy-induced Nausea and Vomiting trials Research Report on Chemotherapy-induced Nausea and Vomiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers Aprepitant Capsule 125 MG, Aprepitant oral suspension 20 mg/mL - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | The Hospital for Sick Children | 17 | 2017-08-10 | 2022-04-11 |
| An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects Rolapitant, Digoxin, Sulfasalazine - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | Tesaro, Inc. | 102 | 2015-05-01 | 2015-08-25 |
| A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers Rolapitant - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | Tesaro, Inc. | 100 | 2015-01-01 | 2015-08-25 |
| An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant Rolapitant - Oral, Rolapitant - IV - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | Tesaro, Inc. | 138 | 2014-09-01 | 2015-08-25 |
| A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 92 | 2009-02-05 | 2018-09-25 |
| A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 42 | 2009-02-01 | 2015-01-28 |
| A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam - Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 188 | 2005-01-01 | 2015-08-19 |
| Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) ondansetron clinical trial formulation, ondansetron marketed formulation - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 45 | 2004-06-01 | 2015-08-19 |
| A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) Comparator: Treatment A (Zofran, ondansetron), Comparator: Treatment B (Zofran, ondansetron), Comparator: Treatment C (Zofran, ondansetron) - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2003-11-01 | 2016-09-14 |
Vomiting (9) · Postoperative Nausea and Vomiting (1)
Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Signs and Symptoms, Digestive (9) · Nausea (1) · Pathologic Processes (1) · Postoperative Complications (1)
Aprepitant (4) · Ondansetron (3) · rolapitant (3) · Dexamethasone (1) · Digoxin (1) · Food (1) · Midazolam (1) · Sulfasalazine (1) · fosaprepitant (1)
Merck Sharp & Dohme LLC (5) · Tesaro, Inc. (3) · The Hospital for Sick Children (1)
United States (3) · Canada (1)
Dennis Vargo, MD (3)